Here is the design of a clinical trial:

Official Title: Favipiravir, Lopinavir/Ritonavir or Combination Therapy: a Randomised, Double Blind, 2x2 Factorial Placebo-controlled Trial of Early Antiviral Therapy in COVID-19

Included conditions:
- COVID-19

Study Armgroups:
- {'label': 'Favipiravir + Lopinavir/ritonavir (LPV/r)', 'type': 'EXPERIMENTAL', 'description': 'Oral favipiravir at 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) at 400mg/100 mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7', 'interventionNames': ['Drug: Favipiravir', 'Drug: Lopinavir/ Ritonavir']}
- {'label': 'Favipiravir + Lopinavir/ritonavir (LPV/r) placebo', 'type': 'EXPERIMENTAL', 'description': 'Oral favipiravir at 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) matched placebo at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7.', 'interventionNames': ['Drug: Favipiravir', 'Other: Lopinavir/ Ritonavir Placebo']}
- {'label': 'Favipiravir placebo + Lopinavir/ritonavir (LPV/r)', 'type': 'EXPERIMENTAL', 'description': 'Oral favipiravir matched placebo at 1800 mg twice daily on Day 1, by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7.', 'interventionNames': ['Drug: Lopinavir/ Ritonavir', 'Other: Favipiravir Placebo']}
- {'label': 'Favipiravir placebo + Lopinavir/ritonavir (LPV/r) placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'Oral favipiravir matched placebo at 1800 mg twice daily on Day 1, by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) matched placebo at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7.', 'interventionNames': ['Other: Favipiravir Placebo', 'Other: Lopinavir/ Ritonavir Placebo']}

Interventions:
- {'type': 'DRUG', 'name': 'Favipiravir', 'description': 'Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.', 'armGroupLabels': ['Favipiravir + Lopinavir/ritonavir (LPV/r)', 'Favipiravir + Lopinavir/ritonavir (LPV/r) placebo'], 'otherNames': ['Avigan']}
- {'type': 'DRUG', 'name': 'Lopinavir/ Ritonavir', 'description': 'Dosage and method of administration: Day 1: 400mg/100 mg twice daily; Day 2 to Day 7: 200mg/50mg four (4) times daily', 'armGroupLabels': ['Favipiravir + Lopinavir/ritonavir (LPV/r)', 'Favipiravir placebo + Lopinavir/ritonavir (LPV/r)'], 'otherNames': ['Kaletra']}
- {'type': 'OTHER', 'name': 'Favipiravir Placebo', 'description': 'Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.', 'armGroupLabels': ['Favipiravir placebo + Lopinavir/ritonavir (LPV/r)', 'Favipiravir placebo + Lopinavir/ritonavir (LPV/r) placebo']}
- {'type': 'OTHER', 'name': 'Lopinavir/ Ritonavir Placebo', 'description': 'Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.', 'armGroupLabels': ['Favipiravir + Lopinavir/ritonavir (LPV/r) placebo', 'Favipiravir placebo + Lopinavir/ritonavir (LPV/r) placebo']}

Primary Outcomes:
- {'measure': 'Upper respiratory tract viral load at Day 5', 'description': 'Quantitative polymerase chain reaction (PCR) performed on saliva samples at Day 5 of therapy', 'timeFrame': 'Day 5 from randomisation'}

Please estimate the sample size based on the assumption: 
Not specified
Numbers to be randomised (sample size)
          240 participants, 60 in each arm.